HIV - Human Immunodeficiency VirusPrimoAVIHNCT07691424
Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France
An observational study of HIV - Human Immunodeficiency Virus and Socio-economic Status, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV - Human Immunodeficiency Virus, Socio-economic Status, Migrants
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 15 Jul 2026to 15 Feb 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults patients living with HIV and receiving care at Clermont-Ferrand Univeristy Hospital between 2010 and 2022
Who may be able to join
- Adults (≥18 years of age);
- Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France.
- Non-inclusion Criteria:
- Patients who declined to participate in the study;
- Patients who do not speak French and for whom no interpretere was available
- Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Clermont-Ferrand University Hospital
Clermont-Ferrand, France, 63000
Aida ZAGHDOUDI, Medical Doctor
About this study
Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival .
The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.
- Keywords
- HIV, socio-economic status, vulnerability, immuno-virological status, migrants
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
HIV immuno-virological status
To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants
Measured: Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start15 Jul 2026 (estimated)
- Primary completion15 Feb 2029 (estimated)
- Study completion15 Feb 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV - Human Immunodeficiency VirusStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Aida ZAGHDOUDI, Principal investigator, University Hospital, Clermont-Ferrand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07691424
- Sponsor's protocol ID
- RNI 2025 ZAGHDOUDI
- Other IDs
- ANSM
- Acronym
- PrimoAVIH
- Status last verified
- Jun 2026
- First submitted
- 2 Jul 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France
- ClinicalTrials.gov ID
- NCT07691424
- Acronym / sponsor ID
- PrimoAVIH / RNI 2025 ZAGHDOUDI
- Keywords
- HIV, socio-economic status, vulnerability, immuno-virological status, migrants
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- 15 Jul 2026 (estimated)
- Primary completion
- 15 Feb 2029 (estimated)
- Study completion
- 15 Feb 2030 (estimated)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival .
The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults patients living with HIV and receiving care at Clermont-Ferrand Univeristy Hospital between 2010 and 2022
Key inclusion criteria (6 listed)
- Adults (≥18 years of age);
- Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France.
- Patients who declined to participate in the study;
- Patients who do not speak French and for whom no interpretere was available
- Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
HIV immuno-virological status
Time frame: Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029
To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for HIV - Human Immunodeficiency Virus
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Aida ZAGHDOUDI principal investigator
University Hospital, Clermont-Ferrand
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV - Human Immunodeficiency Virus and Socio-economic Status, run by University Hospital, Clermont-Ferrand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lise Laclautre (+33473754963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HIV immuno-virological status (time frame: Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.